Cover Image
市場調查報告書

PharmaPoint:潰瘍性大腸炎(UC) - 現在/未來的主要企業

PharmaPoint: Ulcerative Colitis - Current and Future Players

出版商 GlobalData 商品編碼 300577
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:潰瘍性大腸炎(UC) - 現在/未來的主要企業 PharmaPoint: Ulcerative Colitis - Current and Future Players
出版日期: 2014年02月28日 內容資訊: 英文 53 Pages
簡介

本報告網羅急速成長的潰瘍性大腸炎(UC)治療藥市場,以包含新加入廠商的競爭情形為焦點,再加上主要企業相關最新資訊詳細分析,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 市場預測

  • 全球市場
    • 預測
    • 推動因素·障礙 - 全球問題點

第4章 現在/未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Johnson & Johnson
    • AbbVie
    • 武田藥品工業
    • Warner Chilcott
    • Salix Pharmaceuticals/Santarus
    • Shire Pharmaceuticals
    • Ferring Pharmaceuticals
    • Pfizer
    • InDeX Pharmaceuticals

第5章 附錄

圖表

目錄
Product Code: GDHC1029FPR

GlobalData has released its pharma report, "PharmaPoint: Ulcerative Colitis - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Ulcerative Colitis Market. The report identifies and analyses the key companies shaping and driving the global Ulcerative Colitis market. The report provides insight into the competitive Ulcerative Colitis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Ulcerative Colitis
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Ulcerative Colitis sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Ulcerative Colitis market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Ulcerative Colitis market landscape? Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers. Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Johnson. Johnson
    • 4.3.2. AbbVie
    • 4.3.3. Takeda Pharmaceuticals
    • 4.3.4. Warner Chilcott
    • 4.3.5. Salix Pharmaceuticals/Santarus
    • 4.3.6. Shire Pharmaceuticals
    • 4.3.7. Ferring Pharmaceuticals
    • 4.3.8. Pfizer
    • 4.3.9. InDeX Pharmaceuticals

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Diagnosed UC Patients
    • 5.4.2. Percent Drug-Treated Patients
    • 5.4.3. General Pricing Assumptions
    • 5.4.4. Generic Erosion
  • 5.5. Physicians and Specialists Included in This Study
  • 5.6. Primary Research. Prescriber Survey
  • 5.7. About the Authors
    • 5.7.1. Author
    • 5.7.2. Global Head of Healthcare
  • 5.8. About GlobalData
  • 5.9. Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($m) for UC, 2012-2022
  • Table 2: Global UC Market - Drivers and Barriers, 2012-2022
  • Table 3: Key Companies in the UC Market, 2012-2022
  • Table 4: J&J's UC Portfolio Assessment, 2014
  • Table 5: J&J's SWOT Analysis in UC, 2014
  • Table 6: AbbVie's UC Portfolio Assessment, 2014
  • Table 7: AbbVie's UC SWOT Analysis, 2014
  • Table 8: Takeda Pharmaceuticals' UC Portfolio Assessment, 2014
  • Table 9: Takeda's UC SWOT Analysis, 2014
  • Table 10: Warner Chilcott's UC Portfolio Assessment, 2014
  • Table 11: Warner Chilcott's UC SWOT Analysis, 2014
  • Table 12: Salix Pharmaceuticals/Santarus UC Portfolio Assessment, 2013
  • Table 13: Salix Pharmaceuticals/Santarus UC SWOT Analysis, 2014
  • Table 14: Shire Pharmaceuticals' UC Portfolio Assessment, 2014
  • Table 15: Shire Pharmaceuticals' UC SWOT Analysis, 2014
  • Table 16: Ferring Pharmaceuticals' UC Portfolio Assessment, 2013
  • Table 17: Ferring Pharmaceutical's UC SWOT Analysis, 2014
  • Table 18: Pfizer's UC Portfolio Assessment, 2014
  • Table 19: Pfizer's UC SWOT Analysis, 2014
  • Table 20: InDeX Pharmaceuticals' UC Portfolio Assessment, 2013
  • Table 21: InDeX Pharmaceuticals' UC SWOT Analysis, 2014
  • Table 22: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Global Sales for UC by Region, 2012 -2022
  • Figure 2: Company Portfolio Gap Analysis in UC, 2012-2022
Back to Top